Emerging Therapies to Treat Lupus Erythematosus

Lupus erythematosus (LE), a family of chronic autoimmune diseases, ranges from skin disease to life-threatening systemic disease. Multiple therapy options are necessary, even for patients with similar symptoms-and there is great need for agents that can control the complications of systemic disease. LE therapy development is increasing, and many companies are investigating LE as an expansion indication. Get the Answers You Need to Shape Your Strategy The small lupus erythematosus (LE) patient population poses challenges to companies that are developing agents for this indication: enrollment for clinical trials can be diffi cult, and the sales potential of these agents is limited. What are companies doing to surmount these challenges? Although effective, few existing agents for cutaneous LE are considered safe enough for long-term use. An effective agent that is safe for prolonged treatment will have a signifi cant competitive advantage. Which agent now in development has the best chance to satisfy this need? Is any agent currently in development likely to displace current fi rst-line therapies? Because of the heterogeneous nature of systemic LE, the market can support many agents. But owing to the number of effective generics available, emerging agents must prove their greater effi cacy and safety to ensure adoption. What are the advantages and disadvantages of the emerging therapies' modes of action? How soon are new therapies likely to reach the market? What are their prospects for success in competition with generics and established therapies? Please note: the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Mentioned in This Spectrum Report
Therapies
Abatacept
Abetimus sodium
Acitretin
Amcinonide
ASF-1096
Azathioprine
Belimumab
Betamethasone
diproprionate
Celecoxib
Chloroquine
Clobetasol proprionate
Cyclophosphamide
Dapsone
Difl orasone diacetate
Edratide
Efalizumab
Epratuzumab
Etretinate
Hydroxychloroquine
Intravenous gamma
globulin
Isotretinoin
Lefl unomide
Methotrexate
Mycophenolate mofetil
Pimecrolimus
Prasterone
Rituximab
Sirolimus
Tacrolimus
Thalidomide
Triamcinolone acetonide
Companies
Active Biotech
Allergan
Altana
Amgen
Aspreva
Astellas
Astion Pharma
Barr
Baxter
Biogen Idec
Biomarin
Boehringer Ingelheim
Bradley Pharmaceuticals
Bristol-Myers Squibb
Celgene
Connetics
Daiichi Sankyo
Duramed
Elusys Therapeutics
Genelabs Technologies
Genentech
GlaxoSmithKline
Human Genome Sciences
Immunomedics
ImmuPharma
La Jolla Pharmaceuticals
Meda
MedImmune
Merck
Neovacs
Novartis
Pfi zer
QLT
Repligen
Roche
Salix
Sanofi -Aventis
Santen
Schering-Plough
Serono
Shionogi
Shire
Stada
Teva
TolerRX
UCB
Wyeth
Xoma
ZymoGenetics